Drug Trial Radar · NCT07020533
A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant
Last checked: Nov 20, 2026Latest source record: Oct 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
46
Planned (sponsor's estimate)
Start
Sep 9, 2026
Primary completion
Feb 14, 2030
Study completion Feb 14, 2030
Sponsor
- Lead sponsor
- City of Hope Medical CenterAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- National Cancer Institute (NCI)
- First posted
- Jun 13, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This phase Ib trial tests the safety, side effects, and how well cytomegalovirus (CMV)-modified vaccinia Ankara (MVA) Triplex vaccine works in enhancing CMV-specific immunity and preventing CMV viremia in patients undergoing haploidentical hematopoietic stem cell transplant. Haploidentical stem cell transplantation (haploHCT) has advanced to become the predominant procedure for patients lacking a matched donor. Compared to matched related donor transplants, the rate of significant CMV infection is higher in patients undergoing a haploHCT. Significant CMV infection is associated with an increased risk of complications and death. Vaccination is the main preventative approach to limit complications and death in immunocompromised patients at high risk of post-stem cell transplant infections. CMV-MVA Triplex vaccine, is a CMV vaccine based on the attenuated poxvirus, modified vaccinia Ankara (MVA), developed to enhance CMV-specific immunity in both healthy stem cell transplant donors and stem cell transplant patients to prevent significant CMV infection post-stem cell transplant. Giving CMV-MVA triplex vaccine may be safe, tolerable and/or effective in enhancing cytomegalovirus (CMV)-specific immunity and preventing CMV viremia in patients undergoing a haploHCT.
Conditions
- Accelerated Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive
- Acute Lymphoblastic Leukemia
- Acute Myeloid Leukemia
- Chronic Lymphocytic Leukemia
- Chronic Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive
- Hematopoietic and Lymphatic System Neoplasm
- Hodgkin Lymphoma
- Lymphoblastic Lymphoma
- Myelodysplastic Syndrome
- Myelofibrosis
- Myeloproliferative Neoplasm
- Non-Hodgkin Lymphoma
Interventions
Biospecimen CollectionProcedure
Undergo blood sample collection
Electronic Health Record ReviewOther
Ancillary studies
Haploidentical Hematopoietic Cell TransplantationProcedure
Undergo HCT
LetermovirDrug
Given IV or PO
Multi-peptide CMV-Modified Vaccinia Ankara VaccineBiological
Given IM
Myeloablative ConditioningProcedure
Receive myeloablative conditioning
PheresisProcedure
Undergo apheresis
Recombinant Granulocyte Colony-Stimulating FactorBiological
Given G-CSF
Primary outcomes
What the sponsor says the trial is designed to measure.
- Cytomegalovirus (CMV) reactivation prompting antiviral therapyTime frame: From day 0 to day 100 post-hematopoietic stem cell transplant (HCT)
- CMV diseaseTime frame: From day 0 to day 100 post-HCT
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
City of Hope Medical Center
Duarte, California · Recruiting
Northside Hospital
Atlanta, Georgia · Recruiting
Brigham and Women's Hospital
Boston, Massachusetts · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.